1163719-56-9 Usage
Description
CCT196969 is a novel small molecule inhibitor that targets both RAF and SRC kinases. It is a paradox-breaking RAF inhibitor, making it effective against drug-resistant BRAF mutant melanoma. Its unique dual-targeting mechanism allows it to overcome resistance and provide a promising therapeutic option for patients with this type of cancer.
Uses
Used in Oncology:
CCT196969 is used as an anticancer agent for the treatment of drug-resistant BRAF mutant melanoma. It targets both RAF and SRC kinases, making it effective against melanoma cells that have developed resistance to conventional BRAF inhibitors. This dual-targeting approach helps overcome resistance and provides a more effective treatment option for patients with this aggressive form of skin cancer.
Used in Drug Development:
CCT196969 is also used in the development of new cancer therapies, as its unique mechanism of action can potentially be applied to other cancer types with similar resistance mechanisms. Researchers are exploring its potential in combination with other targeted therapies and immunotherapies to enhance treatment outcomes and improve patient survival rates.
Check Digit Verification of cas no
The CAS Registry Mumber 1163719-56-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,6,3,7,1 and 9 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1163719-56:
(9*1)+(8*1)+(7*6)+(6*3)+(5*7)+(4*1)+(3*9)+(2*5)+(1*6)=159
159 % 10 = 9
So 1163719-56-9 is a valid CAS Registry Number.
1163719-56-9Relevant articles and documents
PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE
-
Page/Page column 191, (2009/07/18)
The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.
